ROUSES POINT PHARMS
GenericsROUSES POINT PHARMS is a generic drug manufacturer focused on Neurology.
ROUSES POINT PHARMS's Key Drugs
ROUSES POINT PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ROUSES POINT PHARMS's Recent FDA Approvals
New NDA/BLA approvals for ROUSES POINT PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
ROUSES POINT PHARMS's Therapeutic Areas
ROUSES POINT PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ROUSES POINT PHARMS's Top Competitors
ROUSES POINT PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ROUSES POINT PHARMS Pipeline Snapshot
Active clinical trials for ROUSES POINT PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2012-08-27
- Latest
- 2012-08-27
- Applications
- 1